Click on headlines below to download research

Exploiting the potential of cell therapy
ReNeuron Group | 26/08/2020

ReNeuron has refocussed onto its human retinal progenitor cell (hRPC) as shown in the last business update and in the FY20 results. hRPC, now the lead…

Strong data in retinal therapy shows long effects
ReNeuron Group | 06/07/2020

ReNeuron has released further follow-up data from the ongoing human retinal progenitor cell (hRPC) trial, which shows a robust sustained averaged response.…

Focus on retinal therapy, out-licensing of stroke
ReNeuron Group | 23/06/2020

ReNeuron has changed its focus to concentrate on cell therapy for retinal disorders. The Phase I/II has FDA clearance to use a higher dose and a new UK…